Understanding drug resistance in advanced GIST tumors
Part of Cancer, Digestive system clinical trials.
This study looks at why some GIST tumors stop responding to standard treatments. It uses special imaging and genetic testing of tumor tissue to find resistance patterns, which may guide future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your GIST has stopped responding to or you couldn't tolerate all four standard GIST drugs: imatinib, sunitinib, regorafenib, and ripretinib.
- A doctor has decided that you need a PET-CT scan and possibly a tumor biopsy.
- You have stored tumor tissue from a previous biopsy (FFPE sample).
- You have older CT, MRI, or PET scans available for review.
- You have a tumor lesion that is growing and can be safely biopsied.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This study uses a special MRI technique to see how well imatinib is working on your GIST tumor. It may help doctors understand treatment response better and guide your care.
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
This study follows people who have been taking targeted cancer drugs (called TKIs) for advanced GIST for at least 2 years to understand how these long-term treatments affect quality of life, side effects, and daily living. Researchers want to learn what challenges patients face and how to better support them.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Hear when a new Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.